16,784 Danaher Corporation $DHR Shares Purchased by Venture Visionary Partners LLC

Key Points

• Venture Visionary Partners increased its Danaher holdings by 181.4% in the third quarter, purchasing 16,784 additional shares for a total of 26,039 shares valued at approximately $5.77 million.
• Danaher reported quarterly EPS of $1.94, beating estimates by $0.09, while revenue rose 5.5% year over year to $6.26 billion. Institutional investors own approximately 79.05% of the company.
• Analysts maintain a generally positive outlook, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $235.23, compared with a recent trading price of $218.85.

Venture Visionary Partners LLC raised its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 181.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,039 shares of the conglomerate's stock after buying an additional 16,784 shares during the quarter. Venture Visionary Partners LLC's holdings in Danaher were worth $5,769,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DHR. BlackRock Inc. acquired a new stake in shares of Danaher during the 2nd quarter valued at about $10,492,520,000. State Street Corp raised its position in Danaher by 1.7% in the fourth quarter. State Street Corp now owns 27,681,334 shares of the conglomerate's stock worth $6,345,529,000 after purchasing an additional 472,608 shares in the last quarter. Wellington Management Group LLP raised its position in Danaher by 10.4% in the second quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate's stock worth $3,108,031,000 after purchasing an additional 1,542,310 shares in the last quarter. Jupiter Topco LLC bought a new position in Danaher during the second quarter worth about $1,456,317,000. Finally, Generation Investment Management LLP acquired a new stake in Danaher during the second quarter valued at approximately $1,287,949,000. 79.05% of the stock is owned by institutional investors.

Danaher Price Performance

Shares of DHR stock traded up $3.24 during trading hours on Wednesday, hitting $218.85. 3,974,091 shares of the company's stock were exchanged, compared to its average volume of 4,460,003. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The stock has a market cap of $153.85 billion, a price-to-earnings ratio of 38.87, a price-to-earnings-growth ratio of 2.75 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The stock's 50-day moving average is $210.46 and its 200-day moving average is $194.25.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to analysts' expectations of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The firm's revenue for the quarter was up 5.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.77 earnings per share. As a group, research analysts forecast that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher's payout ratio is currently 28.42%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Wells Fargo & Company lowered their price objective on Danaher from $212.00 to $195.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 22nd. UBS Group assumed coverage on Danaher in a research note on Wednesday, September 9th. They set a "buy" rating and a $250.00 price objective for the company. The Goldman Sachs Group lifted their price objective on Danaher from $210.00 to $250.00 and gave the company a "buy" rating in a report on Monday, September 21st. TD Cowen reduced their target price on shares of Danaher from $240.00 to $236.00 and set a "buy" rating on the stock in a research note on Wednesday, July 22nd. Finally, Barclays upped their target price on shares of Danaher from $230.00 to $255.00 and gave the stock an "overweight" rating in a report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $235.23.

Danaher Company Profile

Danaher Corporation NYSE: DHR is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.